Enhancement of Antitumor Immunity Using a DNA-Based Replicon Vaccine Derived from Semliki Forest Virus

A DNA-based replicon vaccine derived from Semliki Forest virus, PSVK-shFcG-GM/B7.1 ( Fig. 1a ) was designed for tumor immunotherapy as previously constructed. The expression of the fusion tumor antigen (survivin and hCGβ-CTP37) and adjuvant molecular protein (Granulocyte-Macrophage Colony-Stimulatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Liang, Wang, Yue, Xiao, Yi, Wang, Yu, Dong, JinKai, Gao, Kun, Gao, Yan, Wang, Xi, Zhang, Wei, Xu, YuanJi, Yan, JinQi, Yu, JiYun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946523/
https://www.ncbi.nlm.nih.gov/pubmed/24608380
http://dx.doi.org/10.1371/journal.pone.0090551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946523/
https://www.ncbi.nlm.nih.gov/pubmed/24608380
http://dx.doi.org/10.1371/journal.pone.0090551

Ejemplares similares